| |
Frequency/Median |
|
| Category |
with Aining |
without Aining |
p-value# |
| Gender |
|
|
|
| Male |
13 |
5 |
0.161 |
| Female |
20 |
19 |
| |
|
|
|
| Age |
43 |
39 |
0.082 |
| CD4 count (months after treatment) |
|
|
| baseline |
278 |
339.5 |
0.485 |
| 3 months after HAART |
317 |
321.5 |
0.841 |
| 6 months after HAART |
254 |
286 |
0.626 |
| 11 months after HAART |
227 |
218 |
0.968 |
| Annual difference |
-72.5 |
-119 |
0.044 |
| CD8 count |
| baseline |
880 |
735.5 |
0.626 |
| 3 months after HAART |
848 |
586.5 |
0.258 |
| 6 months after HAART |
847 |
686 |
0.516 |
| 11 months after HAART |
675 |
625 |
0.536 |
| Annual difference |
-154 |
-135 |
0.828 |
| CD3 count |
|
|
| baseline |
1130 |
1162.5 |
0.865 |
| 3 months after HAART |
1113 |
923.5 |
0.604 |
| 6 months after HAART |
1217 |
1122 |
0.893 |
| 11 months after HAART |
934 |
913.5 |
0.879 |
| Annual difference |
-197 |
-272 |
0.390 |
| CD45RA count |
|
|
| baseline |
1552 |
1504.5 |
0.892 |
| 3 months after HAART |
1603 |
1169 |
0.465 |
| 6 months after HAART |
1442 |
1616.5 |
0.66 |
| 11 months after HAART |
1228 |
1220 |
0.765 |
| #Wilcoxon rank sum test with continuity correction and Fisher test were performed where appropriate |
|
